Tag Archives: Edwards Lifesciences

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and PerkinElmer (NYSE: PKI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Edwards Lifesciences (EW – Research Report) and PerkinElmer (PKI – Research Report). Edwards Lifesciences (EW) In a report issued on January 31, Josh

Stifel Nicolaus Believes Edwards Lifesciences (NYSE: EW) Still Has Room to Grow

Stifel Nicolaus analyst Rick Wise reiterated a Buy rating on Edwards Lifesciences (EW – Research Report) on January 31 and set a price target of $190. The company’s shares closed on Friday at $168.70, close to its 52-week high of

Edwards Lifesciences (EW) Received its Third Buy in a Row

After Wells Fargo and Cowen & Co. gave Edwards Lifesciences (NYSE: EW) a Buy rating last month, the company received another Buy, this time from Raymond James. Analyst Jayson Bedford maintained a Buy rating on Edwards Lifesciences today and set

Edwards Lifesciences (EW): New Buy Recommendation for This Healthcare Giant

In a report released today, Raj Denhoy from Jefferies maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price target of $180. The company’s shares closed on Tuesday at $157.35. According to TipRanks.com, Denhoy is a

The VP, Corp. Contr of Edwards Lifesciences is Exercising Options

Today it was reported that the VP, Corp. Contr of Edwards Lifesciences (EW – Research Report), Robert Sellers, exercised options to sell 7,859 EW shares at $42.72 a share, for a total transaction value of $1.2M. Following Robert Sellers’ last

Citigroup Maintains Their Sell Rating on Edwards Lifesciences (EW)

In a report released today, Amit Hazan from Citigroup maintained a Sell rating on Edwards Lifesciences (NYSE: EW), with a price target of $118. The company’s shares opened today at $142.57. According to TipRanks.com, Hazan is a 4-star analyst with